PCN37 PRELIMINARY COST-CONSEQUENCE ANALYSIS OF EPIRUBICIN/CISPLATIN/5FU (ECF) COMPARED TO EPIRUBICIN/CISPLATIN/CAPECITABINE (ECX) IN PATIENTS WITH ADVANCED OESOPHAGOGASTRIC CANCER
May 1, 2008, 00:00
10.1016/S1098-3015(10)70215-1
https://www.valueinhealthjournal.com/article/S1098-3015(10)70215-1/fulltext
Title :
PCN37 PRELIMINARY COST-CONSEQUENCE ANALYSIS OF EPIRUBICIN/CISPLATIN/5FU (ECF) COMPARED TO EPIRUBICIN/CISPLATIN/CAPECITABINE (ECX) IN PATIENTS WITH ADVANCED OESOPHAGOGASTRIC CANCER
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)70215-1&doi=10.1016/S1098-3015(10)70215-1
First page :
Section Title :
Open access? :
No
Section Order :
863